No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Biocon’s Biosimilar Insulin Aspart US-Approved as First Interchangeable Biosimilar to Novo Nordisk’s NovoLog®
On 15 July 2025, Biocon Biologics announced that the FDA has approved Kirsty™ (insulin aspart-xjhz) as the first and only interchangeable biosimilar to Novo Nordisk’s Novolog®.